The present invention relates to a novel peptide or a partial sequence thereof for enhancing expression efficiency of a target protein, and a fusion protein comprising the same. The novel peptide according to the present invention can enhance expression efficiency of a target protein, and furthermore, the peptide can also be applied to a solubility-enhancing fusion protein in order to enhance solubility of the target protein, so that solubility as well as expression efficiency of the target protein is enhanced, which allows such a peptide to be usefully used for production of a recombinant target protein.

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Disclosed are methods for treating gouty arthropathy in a subject that is allergic to a uricase. In some aspect, disclosed herein are methods for desensitizing a subject allergic to a uricase.

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Provided is a urate oxidase preparation. The urate oxidase preparation includes polyethylene glycol-modified urate oxidase as an active ingredient and a buffer reagent as an excipient.

Provided is a method for preparing a polyethylene glycol-modified urate oxidase, at least 11 of the following amino acid sites of the polyethylene glycol-modified urate oxidase have a PEG modification: T.sup.1, K.sup.3, K.sup.4, K.sup.30, K.sup.35, K.sup.76, K.sup.79, K.sup.97, K.sup.112, K.sup.116, K.sup.120, K.sup.152, K.sup.179, K.sup.222, K.sup.231, K.sup.266, K.sup.272, K.sup.285, K.sup.291, and K.sup.293, and the preparation method includes: performing a coupling reaction between urate oxidase and polyethylene glycol, wherein the polyethylene glycol is provided in the form of an acidic solution, and a molar ratio of the urate oxidase to the polyethylene glycol is 1: (56 to 94), to obtain the polyethylene glycol-modified urate oxidase.

Provided herein are charge complementary peptides coupled to a cargo polypeptide (e.g., a uricase protein) (e.g., uricase) that are capable of self-assembling under stimulating conditions. The charge complementary peptides can be capable of forming supramolecular structures. Also provided herein are methods of using the charge complementary peptides provided herein (e.g., to treat gout).

A uricase derivative co-conjugated with fatty acid-linked polyethylene glycol derivatives and optionally, alkoxy polyethylene glycol derivatives is presented. The uricase may be intramolecularly crosslinked. The uricase derivative of the present invention is intended for use as a treatment for gout or hyperuricemia.

The subject invention provides a method for purifying a target protein from a mixture comprising the target protein and contaminating protein, comprising the steps of exposing the mixture to an effective amount of a cationic surfactant such that the contaminating protein is preferentially precipitated and recovering the target protein. Proteins purified according to the method of the invention are also provided.

Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.